| 2024-05-15 |
150 |
Order - Memorandum and Order |
Hatch-Waxman Act patent case involving U.S. Patent Nos. 9,561,229 (“the ’229
patent”) and 9,974,794 (…the 229 patent is GRANTED. (4) Heron's motion for summary judgment of claims 111 of the 794 patent is DENIED… (“the ’794 patent”). Plaintiff Heron Therapeutics, Inc. is the owner of both
patents. Heron moves for…all citations to the ’229 patent’s specification also apply to the ’794 patent at the same line
and page…administration.” ’229 patent at col. 1, ll. 47–49.
The asserted patents contain both composition |
External link to document |
| 2024-06-23 |
172 |
Miscellaneous Relief |
inter alia, U.S. Patent Nos. 9,561,229 (“the ’229 patent”) and 9,974,794 (“the
’794 patent”) (collectively…with the additional patents asserted in Heron’s Complaint, “Heron’s
Asserted Patents”), based on Fresenius… 9, 10, and 21 of the ’229 patent; and claims 9 and 10 of the ’794
patent;
NOW THEREFORE, …1-8 and 11-20 of the ’229 patent or claims 1-8 and 11-21 of the ’794
patent.
2. Pursuant…infringes Heron’s Asserted Patents,
except for claims 9, 10, and 21 of the ’229 patent, and claims 9 and 10 |
External link to document |
| 2024-07-01 |
175 |
Redacted Document |
Heron’s U.S. Patent Nos. 9,561,229 (“the ’229
patent”) (JTX-001) and 9,974,794 (“the ’794 patent”) (JTX-007…-007) (collectively, “patents-in-suit”).
The inventions of the patents-in-suit paved the way for the …two patents: two
claims narrowly directed to the formulation (claims 9 and 10 of the ’229 patent), one…formulation is the subject of the patents-in-suit. Heron’s patented formulation is an
emulsion of aprepitant…which was considered by the Patent Office and never became an issued patent or
covered any actual products—and |
External link to document |
| 2023-07-31 |
54 |
Order |
’794
patent”); U.S. Patent No. 10,500,208 (“the ’208 patent”); and U.S. Patent No. 10,953,018 (“the
…various claims of six
patents: U.S. Patent No. 9,561,229 (“the ’229 patent”); U.S. Patent No. 9,808,465 (“the…“the ’465
patent”); U.S. Patent No. 9,974,793 (“the ’793 patent”); U.S. Patent No. 9,974,794 (“the ’794…794
patent and claim 1 of the ’465 patent are representative.
Claim 1 of the ’794 patent recites… 8 of the ’794 patent, claim 1 of the
’465 patent, claims 1 and 15 of the ’793 patent, claim 1 of the |
External link to document |
| 2024-03-08 |
97 |
Stipulation |
alia, U.S. Patent Nos. 9,808,465 (“the ’465 patent”); 9,973,793 (“the
’793 patent”); 10,500,208 (“the ’208…respect to patents other than the ’465 patent,
the ’793 patent, the ’208 patent, and the ’018 patent, and …invalidity of the ’465 patent, the ’793 patent, the ’208 patent, and the ’018 patent; and the parties
have…claims of the ’465
patent, the ’793 patent, the ’208 patent, and the ’018 patent under 35 U.S.C. § 271… claims of the ’465 patent, the ’793
patent, the ’208 patent, and the ’018 patent.
3. All |
External link to document |
